Stocks
Alexar Therapeutics, Inc.ALXA
YHDHealthcareBiotechnology
A clinical-stage biopharmaceutical company developing inhaled therapies for respiratory diseases, including a lead candidate for cystic fibrosis. Its pipeline focuses on delivering drugs directly to the lungs to improve efficacy and reduce systemic side effects. Investors track ALXA for its progress in Phase 2 and Phase 3 trials and potential partnerships with larger pharmaceutical firms.
Congressional Interest in Alexar Therapeutics, Inc. (ALXA)
1 member of Congress has disclosed 1 trade in Alexar Therapeutics, Inc. (ALXA), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading ALXA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-04-15 | SUSAN BROOKS | buy | $1K-$15K |